PMID-15867098 – GnRH Agonists in Prostate Cancer Treatment
Labrie F. "GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer," Endocrine Reviews, 2005;26(3):361-379. doi:10.1210/er.2004-0017
Quick Reference
| Property | Value |
|---|---|
| PMID | 15867098 |
| DOI | 10.1210/er.2004-0017 |
| Year | 2005 |
| Journal | Endocrine Reviews |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | GnRH agonists (Leuprolide, Goserelin, Triptorelin, Buserelin) |
Key Findings
- GnRH agonists revolutionized prostate cancer treatment by providing a reversible alternative to surgical castration (orchiectomy) for androgen deprivation therapy (ADT)
- Combined androgen blockade (GnRH agonist + antiandrogen) achieves approximately 90% cure rates in localized prostate cancer when initiated at diagnosis
- GnRH agonists suppress testicular testosterone to castrate levels within 2-4 weeks, though an initial testosterone "flare" occurs in the first 1-2 weeks
- The review synthesizes decades of clinical data showing that early intervention with combined androgen blockade significantly improves disease-free and overall survival compared to delayed treatment
- Intracrinology — the local synthesis and action of androgens in peripheral tissues — explains why blocking both testicular and adrenal androgen sources is critical
- Long-acting depot formulations (1-, 3-, 4-, and 6-month) dramatically improved patient compliance and quality of life compared to daily injections or surgical castration
Study Design
Landmark narrative review by Fernand Labrie, a pioneer in GnRH agonist therapy and combined androgen blockade. Synthesizes clinical trial data, endocrinological mechanisms, and treatment outcomes spanning over two decades of GnRH agonist use in prostate cancer management.
Limitations
- Single-author narrative review reflecting the author's own body of work, potentially introducing bias toward combined androgen blockade
- Some of the cited clinical data predates modern PSA-era screening and staging
- Does not address GnRH antagonists, which were emerging at the time
- Cardiovascular and metabolic side effects of long-term ADT not comprehensively addressed
Clinical Relevance
This landmark review established the clinical foundation for GnRH agonist-based androgen deprivation therapy as the standard of care in prostate cancer. It is essential reading for understanding how peptide-based hormonal manipulation replaced surgical approaches. The principles of combined androgen blockade described here remain relevant to current prostate cancer management, though GnRH antagonists have since emerged as alternatives with potentially fewer cardiovascular side effects.
Related
#research #narrative-review #evidence-level-V #cancer